NCT01803022已完成不适用
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 419
- 试验地点
- 1
- 主要终点
- Prescription conditions and use of Low Molecular Weight Heparin in the French usual practice for the treatment of symptomatic Venous Thromboembolism in patients with cancer at up to 6 months
研究概览
简要总结
The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism. This study also aims at gathering epidemiological data on the Low Molecular Weight Heparin therapy of Venous Thromboembolism in patients with cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must provide informed consent
- •Men or women aged 18 years or more
- •Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low Molecular Weight Heparin before entry into the study
排除标准
- •Contraindication to the use of Low Molecular Weight Heparin
结局指标
主要结局
Prescription conditions and use of Low Molecular Weight Heparin in the French usual practice for the treatment of symptomatic Venous Thromboembolism in patients with cancer at up to 6 months
时间窗: up to 6 months
次要结局
- To evaluate the anticoagulant treatment perception and satisfaction by patients with cancer disease with a validated questionnaire(up to 6 months)
- To evaluate Venous Thromboembolism recurrences, bleeding, thrombocytopenia and deaths during Low Molecular Weight Heparin treatment(up to 6 months)
- To describe clinical factors associated with treatment duration with Low Molecular Weight Heparin and those associated with the occurrence of Venous Thromboembolism in patients with cancer(up to 6 months)
- To evaluate the consistency of the Low Molecular Weight Heparin use with French national recommendations on the treatment of Venous Thromboembolism in patients with cancer.(up to 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pharmacokinetics of Low Molecular Weight Heparin in Cancer PatientsCancerThrombosisAngina PectorisNCT00716898Shaare Zedek Medical Center25
已完成
4 期
The Use of Low Molecular Weight Heparin in Traumatic Brain InjuryVenous ThrombosisBrain InjuryNCT00170378Hennepin Healthcare Research Institute300
已完成
不适用
Evaluation of the Effectiveness of Prophylactic LMWH by ThromboelastographyMalignancyNCT06484231Ege University25
终止
不适用
LMWH to Prevent Preeclampsia and Fetal Growth RestrictionPreeclampsiaNCT00260520University of Florence
已完成
2 期
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid SyndromeRecurrent AbortionNCT01051778Cairo University60